Pharmaceuticals · 2021 · 54 citations · 41 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryCancer NanomedicineNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle Delivery SystemsNanoparticle FormulationsDrug Co-deliveryDrug Delivery NanocarriersNanocarriersNanoparticle DeliveryNanoparticlesNiosomal NanocarriersNiosome Drug DeliveryTargeted Delivery
Breast cancer is one of the most prevalent causes of cancer mortality in women. In order to increase patient prognosis and survival rates, new technologies are urgently required to deliver therapeutics in a more effective and efficient manner. Niosome nanoparticles have been recently employed as therapeutic platforms capable of loading and carrying drugs within their core for both mono and combination therapy. Here, niosome-based nanoscale carriers were investigated as a targeted delivery system for breast cancer therapy. The platform developed consists of niosomes loaded with letrozole and cyclophosphamide (NLC) and surface-functionalized with a folic-acid-targeting moiety (NLCPFA). Drug release from the formulated particles exhibited pH-sensitive properties in which the niosome showed low and high release in physiological and cancerous conditions, respectively. The results revealed a synergic effect in cytotoxicity by co-loading letrozole and cyclophosphamide with an efficacy increment in NLCPFA use in comparison with NLC. The NLCPFA resulted in the greatest drug internalization compared to the non-targeted formulation and the free drug. Additionally, downregulation of cyclin-D, cyclin-E, MMP-2, and MMP-9 and upregulating the expression of caspase-3 and caspase-9 genes were observed more prominently in the nanoformulation (particularly for NLCPFA) compared to the free drug. This exciting data indicated that niosome-based nanocarriers containing letrozole and cyclophosphamide with controlled release could be a promising platform for drug delivery with potential in breast cancer therapy.
41
Breast cancer statistics, 2019
Carol DeSantis, Jiemin Ma, Mia M. Gaudet et al. · CA A Cancer Journal for Clinicians · 2019 · 3.2K citations · Full text
Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry
Jie Zhao, Brian David Dynlacht, Takashi Imai et al. · Genes & Development · 1998 · 227 citations · Full text
Robabehbeygom Ghafelehbashi, Iman Akbarzadeh, Mohammad Tavakkoli Yaraki et al. · International Journal of Pharmaceutics · 2019 · 163 citations